Strategic leadership Recent executive and board additions, including a new CEO Maurice Phelan and industry veteran Maik Jornitz, alongside a new investment from Sheridan Capital Partners, indicate strong strategic direction and potential for expanded partnerships and capital-backed growth initiatives.

Investment signals Sheridan Capital Partners’ investment coupled with leadership changes suggests available capital for growth initiatives, partnerships, and expansion of supplier relationships within biopharma and biotech manufacturing.

Biopharma focus Strong emphasis on critical fluid flow products for pharmaceutical and biotech manufacturing, including single-use offerings and sanitary flow components, positions the company to expand cross-sell with established biopharma manufacturers and contract manufacturers.

Strategic partnerships Recent collaborations with AdvantaPure for sustainable tubing launches and Qosina for FlowLinX sanitary components indicate avenues to co-market and co-develop complementary product bundles with established distributors and OEMs.

Growth signals Revenue range of 50 to 100 million and a mid-size employee base suggest scalability opportunities to target larger pharma suppliers, CMOs, and integrators with integrated flow solutions and logistics capabilities.